Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 31;11(1):3-10.
doi: 10.1016/j.ijnss.2023.12.014. eCollection 2024 Jan.

Comparison of the performance of four screening tools for sarcopenia in patients with chronic liver disease

Ting Yu  1   2 , Shanshan Liu  1   2 , Jing Zhao  3 , Yan Jiang  1   2 , Rong Deng  3
Affiliations

Comparison of the performance of four screening tools for sarcopenia in patients with chronic liver disease

Ting Yu et al. Int J Nurs Sci. .

Abstract

Objectives: Early identification of sarcopenia in patients with chronic liver disease is crucial for patient management and prevention of severe complications. We aimed to assess the effectiveness of Ishii score, Strength, Assistance with Walking, Rise from a Chair, Climb Stairs and Falls (SARC-F), SARC-F and Calf Circumference (SARC-CalF), and Mini Sarcopenia Risk Assessment-7 (MSRA-7) to screen sarcopenia in patients with chronic liver disease.

Methods: This prospective study included patients with chronic liver disease in the infectious department of a tertiary hospital in Sichuan, China. Ishii score, SARC-F, SARC-CalF, and MSRA-7 were used to screen for sarcopenia risk. Sarcopenia was diagnosed according to the Asian Myometriosis Working Group (AWGS) 2019, which was used as the gold standard to compare the performance of the four screening tools. We completed clinical registration on the Chinese Clinical Trial Registration website (ChiCTR2100043910).

Results: A total of 366 patients with chronic liver disease (22.4% women, mean age 48.96 ± 11.88 years) were evaluated. Based on the AWGS 2019 standard, the prevalence of sarcopenia in patients with chronic liver disease was 17.5%. Among all participants, receiver operating characteristic (ROC) produced an area under the curve (AUC) of 0.82 for Ishii score (sensitivity 85.94%, specificity 78.15%), 0.53 for SARC-F (sensitivity 6.25%, specificity 99.34%), 0.64 for SARC-CalF (sensitivity 45.31%, specificity 83.11%), and 0.55 for MSRA-7 (sensitivity 87.50%, specificity 22.85%). Based on AUC, decision curve analysis, and calibration curves, we concluded that Ishii score was the most accurate screening tool and was superior to the other tools.

Conclusions: Ishii score is more suitable for screening sarcopenia in patients with chronic liver disease than the SARC-F, SARC-CalF, and MSRA-7, based on the AWGS 2019 criteria. Nursing professionals can use Ishii score as a clinical tool to screen for sarcopenia in patients with chronic liver disease, providing an indication cue for the final diagnosis of sarcopenia, improving diagnostic efficiency, and enabling early identification and prevention of complications resulting from sarcopenia.

Keywords: Chronic liver disease; Ishii score; Risk assessment; Sarcopenia; Screening.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Fig. 1
Fig. 1
ROC curves analysis for the screening tools for the prediction of sarcopenia risk with the AWGS 2019 as a criterion. Diagonal segments are produced by sites.
Fig. 2
Fig. 2
Calibration curves analysis for the screening tools to predict the risk of sarcopenia.
Fig. 3
Fig. 3
Decision curves analysis for the screening tools to predict the risk of sarcopenia. Comparison of the performance of 4 screening tools for sarcopenia in patients with chronic liver disease.
See this image and copyright information in PMC

References

    1. Sieber C. Malnutrition and sarcopenia. Aging Clin Exp Res. 2019;31(6):793–798. doi: 10.1007/s40520-019-01170-1. - DOI - PubMed
    1. Shaw S.C., Dennison E.M., Cooper C. Epidemiology of sarcopenia: Determinants throughout the lifecourse. Calcif Tissue Int. 2017;101(3):229–247. doi: 10.1007/s00223-017-0277-0. - DOI - PMC - PubMed
    1. Cruz-Jentoft A.J., Bahat G., Bauer J., Boirie Y., Bruyère O., Cederholm T., et al. Sarcopenia: Revised European consensus on definition and diagnosis. Age Ageing. 2019;48(4):601. doi: 10.1093/ageing/afz046. - DOI - PMC - PubMed
    1. Petermann-Rocha F., Balntzi V., Gray S.R., Lara J., Ho F.K., Pell J.P., et al. Global prevalence of sarcopenia and severe sarcopenia: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2022;13(1):86–99. doi: 10.1002/jcsm.12783. - DOI - PMC - PubMed
    1. Wu Y.H., Hwang A.C., Liu L.K., Peng L.N., Chen L.K. Sex differences of sarcopenia in Asian populations: the implications in diagnosis and management. J Clin Gerontol Geriatr. 2016;7(2):37–43. doi: 10.1016/j.jcgg.2016.04.001. - DOI

LinkOut - more resources